Eric P. Winer is chief of the Division of Women's Cancers and director of the Breast Oncology Program in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Massachusetts. He also serves as the Institute's chief strategy officer. He is the Thompson Senior Investigator in Breast Cancer Research and a Professor of Medicine at Harvard Medical School. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He has focused his career on treating patients with breast cancer and advancing understanding of the disease. He is committed to delivering the best care to his patients today while striving to improve the methods of care for the future.
Winer has conducted numerous clinical trials during his career. These trials span virtually all aspects of breast cancer. For over a decade, he was the co-chair of the CALGB/Alliance Breast Cancer Committee. Currently, he is the principal investigator of the Dana-Farber/Harvard Cancer Center NCI SPORE in breast cancer. His research group focuses on improving care through the development of new treatment approaches. He also recognizes the importance of de-escalating therapy in patients who can do just as well with less treatment. In collaboration with the Department of Defense and the National Cancer Institute, Winer is also the principal investigator on a study sponsored by the Alliance for Clinical Trials in Oncology, assessing the use of aspirin as adjuvant therapy for node-positive breast cancer patients.
Articles
Winer has authored over 250 publications. Here is a selection of Winer's recently published articles:
Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer. JAMA. 2006;295:1658-67.
Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine. 2009;360:2055-2065.
Sikov WM, Berry DA, Perou CM, et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603. Journal of Clinical Oncology. 2015;33:13-21.
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine. 2015;372:134-41.
Ni J, Ramkissoon SH, Xie S, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancerbrain metastases. Nature Medicine. 2016;22:723-6.
Awards
Claire W. and Richard P. Morse Research Award, Dana-Farber Cancer Institute, 2002
Tisch Award for Outstanding Achievement, Dana-Farber Cancer Institute, 2006